Table 5.

Multivariate association of survival with name, lipophilicity, potency, and intensity of statin use after diagnosis of HCC

VariablesCategoryn (% Among statin users)Adjusted HR (95% CI)P
Statin name
Atorvastatin vs. no statin120 (35%)1.17 (0.88–1.55)0.28
Lovastatin vs. no statin78 (22.7%)0.92 (0.65–1.32)0.66
Pravastatin vs. no statin45 (13.1%)0.82 (0.50–1.34)0.42
Rosuvastatin vs. no statin29 (8.5%)0.85 (0.48–1.49)0.56
Simvastatin vs. no statin168 (49%)0.91 (0.70–1.19)0.51
Statin type
Hydrophilic vs. no statin71 (20.7%)0.80 (0.54–1.19)0.27
Lipophilic vs. no statin302 (88%)1.03 (0.84–1.26)0.80
Statin intensity
Low vs. no statin50 (14.6%)0.88 (0.57–1.37)0.58
Moderate vs. no statin232 (67.6%)0.97 (0.77–1.22)0.78
High vs. no statin61 (17.8%)1.13 (0.76–1.68)0.55

NOTE: Fluvastatin data are not presented as cell count was less than 11.

Abbreviations: CI, confidence interval; HR, hazard ratio for statin use.